NCI Seeks Proposals for Cell Therapy and Viral Vector Production

NCI Division of Cancer Treatment & Diagnosis (DCTD)
Application or LOI Due Date
Applications are accepted three times per year. Submission deadlines: 6/15/21, 10/15/21, 2/15/22, 6/15/22, 10/15/22
Brief Description

NCI’s Division of Cancer Treatment and Diagnosis (DCTD) is excited to announce the availability of cell therapy and viral vector manufacturing capabilities to support the clinical development of cell-based immunotherapy.

Following our initial efforts to support the production of CAR T-cells for multi-center clinical trials, the NCI Biopharmaceutical Development Program at the Frederick National Laboratory for Cancer Research is now offering viral vector production for the genetic modification step in cell therapy manufacturing.

Investigators in need of clinical grade vector and/or cell therapy product manufacturing can submit project proposals to the NCI Experimental Therapeutics (NExT Program).

Additional background on NCI’s cell therapy initiative:
NCI Initiative Aims to Boost CAR T-cell Therapy Clinical Trials
NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials